CL2004000392A1 - Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra - Google Patents

Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra

Info

Publication number: CL2004000392A1
Authority: CL; Chile
Prior art keywords: pharmaceutical composition; compounds; trisustituidos; dislipidemia; oxazol
Prior art date: 2003-02-27

Application number

CL200400392A

Other languages

English (en)

Inventor

Kirk Glombik Heiner Fa Gretzke

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-27

Publication date

2005-04-22

2004-02-27 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2005-04-22 Publication of CL2004000392A1 publication Critical patent/CL2004000392A1/es

Links

150000001875 compounds Chemical class 0.000 title 2
239000008194 pharmaceutical composition Substances 0.000 title 2
206010022489 Insulin Resistance Diseases 0.000 title 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

CL200400392A 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra CL2004000392A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10308355A DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number	Publication Date
CL2004000392A1 true CL2004000392A1 (es)	2005-04-22

Family

ID=32920629

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL200400391A CL2004000391A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.
CL200400392A CL2004000392A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL200400391A CL2004000391A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.

Country Status (34)

Country	Link
US (5)	US7365084B2 (es)
EP (3)	EP1599455B1 (es)
JP (3)	JP2006519199A (es)
KR (3)	KR20050105492A (es)
CN (3)	CN100439347C (es)
AR (3)	AR043432A1 (es)
AT (3)	ATE365159T1 (es)
AU (3)	AU2004215673B2 (es)
BR (3)	BRPI0407814A (es)
CA (3)	CA2517381A1 (es)
CL (2)	CL2004000391A1 (es)
CO (2)	CO5690580A2 (es)
DE (4)	DE10308355A1 (es)
DK (3)	DK1599453T3 (es)
EC (2)	ECSP055985A (es)
ES (3)	ES2287700T3 (es)
HR (3)	HRP20050742A2 (es)
IL (2)	IL170314A (es)
MA (3)	MA27736A1 (es)
MX (3)	MXPA05008995A (es)
NO (3)	NO20054398L (es)
OA (2)	OA13034A (es)
PA (1)	PA8596801A1 (es)
PE (3)	PE20050293A1 (es)
PL (3)	PL378437A1 (es)
PT (3)	PT1599453E (es)
RS (1)	RS20050594A (es)
RU (3)	RU2005130002A (es)
SA (1)	SA04250153A (es)
TN (2)	TNSN05206A1 (es)
TW (3)	TW200510352A (es)
UY (2)	UY28210A1 (es)
WO (3)	WO2004076426A1 (es)
ZA (2)	ZA200505768B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7576131B2 (en) *	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) *	2004-08-07	2006-08-31	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039533B4 (de) *	2004-08-14	2006-09-28	Sanofi-Aventis Deutschland Gmbh	Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de) *	2004-12-15	2006-07-20	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
JP2009509988A (ja)	2005-09-29	2009-03-12	サノフィ−アベンティス	フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
WO2008018138A1 (fr)	2006-08-10	2008-02-14	Wood One Co., Ltd.	Composition hypoglycémique contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
CN105732376A (zh)	2007-08-16	2016-07-06	索尔维公司	制备4-氟取代的3-氧代-烷酸酯的方法
NZ587261A (en)	2008-02-29	2012-05-25	Nissan Chemical Ind Ltd	Process for producing thiophene compound and intermediate thereof
US7615661B2 (en) *	2008-03-12	2009-11-10	International Flavors & Fragrances Inc.	Thioester compounds and their use in fragrance or flavor applications
WO2019117317A1 (ja)	2017-12-13	2019-06-20	キヤノン株式会社	カートリッジ及び画像形成装置
CN109810071B (zh) *	2019-03-28	2023-04-21	中国科学院成都生物研究所	一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) *	1990-06-19	1992-09-11	Commissariat Energie Atomique	Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en)	1996-01-17	1997-07-24	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
HU227021B1 (en)	1996-08-30	2010-05-28	Novo Nordisk As	Glp-1 derivatives
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
HUP0301101A3 (en)	1996-12-31	2009-03-30	Reddy S Res Foundation	Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja)	1997-07-16	2001-07-31	ノボノルディスクアクティーゼルスカブ	縮合化１，２，４−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506757B1 (en) *	1998-03-10	2003-01-14	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
KR100613175B1 (ko) *	1998-08-27	2006-08-17	오노 야꾸힝 고교 가부시키가이샤	카르복실산 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de)	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) *	1999-04-16	2005-06-21	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
EP1173438A1 (en)	1999-04-16	2002-01-23	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
KR100693771B1 (ko) *	1999-04-28	2007-03-12	사노피-아벤티스 도이칠란트 게엠베하	Ｐｐａｒ 수용체 리간드로서의 트리아릴 산 유도체 및 이를 포함하는 약제학적 조성물
CZ20013833A3 (cs)	1999-04-28	2002-02-13	Aventis Pharma Deutschland Gmbh	Deriváty kyselin se dvěma arylovými zbytky jako ligandy receptorů PPAR a farmaceutické prostředky, které je obsahují
WO2000066585A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
EP1194146B1 (en)	1999-06-18	2006-07-19	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
AU5784000A (en)	1999-07-09	2001-01-30	Cohesion Technologies, Inc.	Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof
JP2003506365A (ja)	1999-07-29	2003-02-18	イーライ・リリー・アンド・カンパニー	ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン：セロトニンアゴニスト
CZ2002767A3 (cs) *	1999-09-01	2002-06-12	Aventis Pharma Deutschland Gmbh	Sulfonylkarboxamidové deriváty, způsob jejich přípravy a jejich pouľití jako léčiv
TW200528436A (en)	1999-09-22	2005-09-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
DE60008921T2 (de)	1999-12-03	2005-01-20	Astrazeneca Ab	Kristalline form von (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenyl-ethoxy)phenyl]propansäure
IL151368A0 (en)	2000-03-31	2003-04-10	Probiodrug Ag	Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions
US6770133B2 (en)	2000-04-25	2004-08-03	Kyorin Pharmaceutical Co., Ltd.	Stable crystal of thiazolidinedione derivative and process for producing the same
DK1277736T3 (da)	2000-04-28	2007-10-01	Asahi Kasei Pharma Corp	Hidtil ukendte bicykliske forbindelser
ES2252230T3 (es)	2000-05-11	2006-05-16	Bristol-Myers Squibb Company	Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
CA2410597A1 (en)	2000-05-30	2001-12-06	Merck & Co., Inc.	Melanocortin receptor agonists
YU91002A (sh)	2000-06-09	2006-05-25	Aventis Pharma Deutschland	Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) *	2000-08-11	2002-02-27	Yissum Research Development Company of the Hebrew University of Jerusalem	Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
CA2418104A1 (en) *	2000-08-23	2002-02-28	Eli Lilly And Company	Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001284658A1 (en)	2000-08-23	2002-03-13	Eli Lilly And Company	Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja)	2000-12-05	2004-04-08	杏林製薬株式会社	置換カルボン酸誘導体
GB0031103D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
RS50864B (sr)	2000-12-21	2010-08-31	Sanofi-Aventis Deutschland Gmbh.	Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
KR100635315B1 (ko) *	2000-12-25	2006-10-18	오노 야꾸힝 고교 가부시키가이샤	디히드로나프탈렌 유도체 화합물 및 이 화합물을 유효성분으로 하는 약제
BR0207285A (pt) *	2001-02-15	2004-02-10	Pfizer Producs Inc	Agonistas de ppar
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
KR20040030658A (ko) *	2001-06-07	2004-04-09	일라이 릴리 앤드 캄파니	페록시좀 증식제 활성화 수용체의 조절제
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
WO2003004458A1 (en)	2001-07-03	2003-01-16	Biovitrum Ab	New compounds
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
KR100915108B1 (ko)	2001-08-31	2009-09-03	사노피-아벤티스 도이칠란트 게엠베하	Ｐｐａｒ-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물
WO2003066581A1 (en)	2002-02-05	2003-08-14	Eli Lilly And Company	Urea linker derivatives for use as ppar modulators
DE10215907A1 (de)	2002-04-11	2003-11-06	Aventis Pharma Gmbh	Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en)	2002-07-09	2004-01-15	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) *	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
2004
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Application Discontinuation
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Application Discontinuation
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de active Application Filing
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de active IP Right Grant
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Application Discontinuation
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de active Application Filing
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 US US10/789,017 patent/US7335671B2/en active Active
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 US US10/788,996 patent/US7259177B2/en active Active
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
2005
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2005-08-26 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2005-08-26 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1599452B1 (de)	2007-06-20
HRP20050744A2 (en)	2006-09-30
CO5690580A2 (es)	2006-10-31
CN1753879A (zh)	2006-03-29
US7335671B2 (en)	2008-02-26
DK1599453T3 (da)	2009-08-24
KR20050106461A (ko)	2005-11-09
WO2004076428A1 (de)	2004-09-10
US20080167354A1 (en)	2008-07-10
DE502004004139D1 (de)	2007-08-02
NO20054396D0 (no)	2005-09-22
US20050215596A1 (en)	2005-09-29
ECSP055986A (es)	2006-01-16
WO2004076426A1 (de)	2004-09-10
PL378130A1 (pl)	2006-03-06
ATE365159T1 (de)	2007-07-15
CA2516620A1 (en)	2004-09-10
CN1753881A (zh)	2006-03-29
MA27742A1 (fr)	2006-02-01
ATE430738T1 (de)	2009-05-15
OA13035A (en)	2006-11-10
UY28209A1 (es)	2004-09-30
ATE435217T1 (de)	2009-07-15
CA2517386A1 (en)	2004-09-10
CN1756748A (zh)	2006-04-05
JP2006519194A (ja)	2006-08-24
ECSP055985A (es)	2006-01-16
RS20050594A (en)	2007-12-31
DE502004009690D1 (de)	2009-08-13
EP1599455A1 (de)	2005-11-30
TW200508210A (en)	2005-03-01
PL377735A1 (pl)	2006-02-20
HRP20050743A2 (en)	2006-08-31
IL170316A (en)	2010-11-30
NO20054408D0 (no)	2005-09-22
AR043432A1 (es)	2005-07-27
AU2004215672B2 (en)	2010-01-07
OA13034A (en)	2006-11-10
EP1599453A1 (de)	2005-11-30
DK1599455T3 (da)	2009-11-09
MXPA05008951A (es)	2005-11-04
RU2005129995A (ru)	2006-01-27
JP2006519193A (ja)	2006-08-24
KR20050106462A (ko)	2005-11-09
EP1599452A1 (de)	2005-11-30
AU2004215673A1 (en)	2004-09-10
HRP20050742A2 (en)	2006-09-30
PT1599455E (pt)	2009-09-29
NO20054408L (no)	2005-11-23
PA8596801A1 (es)	2004-09-16
PE20050293A1 (es)	2005-05-24
US7872034B2 (en)	2011-01-18
EP1599453B1 (de)	2009-05-06
TW200510352A (en)	2005-03-16
AU2004215672A1 (en)	2004-09-10
BRPI0407907A (pt)	2006-02-14
CN100398526C (zh)	2008-07-02
US20050101637A1 (en)	2005-05-12
AU2004215673B2 (en)	2009-10-01
PL378437A1 (pl)	2006-04-03
BRPI0407814A (pt)	2006-02-14
UY28210A1 (es)	2004-09-30
US7365084B2 (en)	2008-04-29
US20080015238A1 (en)	2008-01-17
MA27737A1 (fr)	2006-02-01
MA27736A1 (fr)	2006-02-01
ZA200505768B (en)	2005-11-23
RU2005129992A (ru)	2006-02-10
CL2004000391A1 (es)	2005-01-07
JP2006519199A (ja)	2006-08-24
CA2517381A1 (en)	2004-09-10
BRPI0407758A (pt)	2006-02-14
ZA200505765B (en)	2006-05-31
DE502004009453D1 (de)	2009-06-18
PE20040959A1 (es)	2005-01-17
ES2329366T3 (es)	2009-11-25
CN100439347C (zh)	2008-12-03
MXPA05008995A (es)	2005-10-18
RU2005130002A (ru)	2006-01-27
MXPA05008988A (es)	2005-10-18
ES2326418T3 (es)	2009-10-09
EP1599455B1 (de)	2009-07-01
IL170314A (en)	2010-11-30
ES2287700T3 (es)	2007-12-16
NO20054396L (no)	2005-11-11
AR043427A1 (es)	2005-07-27
TNSN05204A1 (en)	2007-06-11
TNSN05206A1 (en)	2007-06-11
CO5690578A2 (es)	2006-10-31
DE10308355A1 (de)	2004-12-23
TW200500349A (en)	2005-01-01
KR20050105492A (ko)	2005-11-04
US7259177B2 (en)	2007-08-21
CN100439345C (zh)	2008-12-03
AU2004215677B2 (en)	2010-01-07
PT1599453E (pt)	2009-07-14
US20040209920A1 (en)	2004-10-21
NO20054398L (no)	2005-11-02
NO20054398D0 (no)	2005-09-22
AU2004215677A1 (en)	2004-09-10
AR043433A1 (es)	2005-07-27
DK1599452T3 (da)	2007-10-01
PE20050292A1 (es)	2005-05-24
WO2004076427A1 (de)	2004-09-10
PT1599452E (pt)	2007-09-12
SA04250153A (ar)	2005-12-03

Publication	Publication Date	Title
CL2004000392A1 (es)	2005-04-22	Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra
CL2007001918A1 (es)	2008-03-28	Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
DE60142890D1 (de)	2010-10-07	3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
CL2004001069A1 (es)	2005-04-01	Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
CL2007001915A1 (es)	2008-01-18	Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
BRPI0807290A2 (pt)	2016-10-11	"composição medicinal para absorção transdérmica, unidade de armazenamento de composição medicinal e prepraração de absorção transdérmica usando a mesma"
CL2004000889A1 (es)	2005-03-18	COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
EE200300080A (et)	2005-02-15	Polüarüülkarboksamiidühendid, nende valmistamine ja kasutamine lipiiditaset alandavate toimeainetena ning neid sisaldav farmatseutiline kompositsioon
BR9711098B1 (pt)	2011-10-04	compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
BRPI0407755B1 (pt)	2013-09-24	composiÇço catalÍtica, sua preparaÇço e uso
ATE380023T1 (de)	2007-12-15	Orale feste pharmazeutische zusammensetzungen zur ph-abhängig mehrphasigen freisetzung
BRPI0517701A (pt)	2008-10-21	uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
BRPI0312649A2 (pt)	2017-05-16	compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
IL183982A0 (en)	2007-10-31	Controlled release formulation for oral administration for treating diabetes containing metformin and methods for the preparation thereof
EE05269B1 (et)	2010-02-15	Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
CL2008003153A1 (es)	2009-07-24	Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
FR2861074B1 (fr)	2006-04-07	Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EE200300171A (et)	2003-06-16	Kristalliline monohüdraat, meetodid selle valmistamiseks ja selle kasutamine farmatseutilise kompositsiooni valmistamiseks
BRPI0519280A2 (pt)	2009-01-06	composto, composiÇço farmacÊutica e uso de um composto
BRPI0415825A (pt)	2007-01-02	novos derivados de tetrahidroespiro{piperidino-2,7'-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6
DK1119557T3 (da)	2004-04-13	Indeno-, naphto- og benzocyclohepta-dihydrothiazolderivater, fremstilling deraf og anvendelse deraf som anorektiske medikamenter
CL43489B (es)	2005-01-21	Compuestos derivados de difenilazetidinona y su sal farmaceuticamente aceptable; composicion faramceutica; compuestos intermediarios; procedimiento para preparar la composicion farmaceutica; y uso de los compuestos para tratar la hiperlipidemia, sint
ITMI20021427A0 (it)	2002-06-28	Composizioni per uso nell'alimentazione animale comprendente una matrice a rilascio controllato procedimento di preparazione e relativo impi
EE200200399A (et)	2003-10-15	Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
ATE499939T1 (de)	2011-03-15	Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend